Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

There are 20 cell and gene therapies on Europe's market versus 43 in the U.S. Find out more about this ecosystem.

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

Various PD-1 and PD-L1 checkpoint inhibitors have been approved by U.S. regulators including blockbuster drugs Keytruda, Imfinzi, and Opdivo to treat different types of cancer. But that hasn’t stopped ...

The month of December 2024 saw a variety of biotech deals take place to advance therapies across different stages in ...

As the year unfolds the biotech industry will look closely at these ten first-in-class drugs on track to reach FDA approval ...

CRISPR-Cas9 is one of the biggest discoveries of the 21st century. Since it was developed in 2012, this gene-editing tool has revolutionized biology research, making it easier to study disease and ...

In the last year or so, there have been a number of indications that Saudi Arabia is setting itself up to become a global biotech hub. Over the next decade, it is expected to become a world leader in ...

Earlier this week, Star Therapeutics’ von Willebrand disease candidate – VGA039 – was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). While it is the most common ...

A blockbuster drug is a therapy that generates at least $1 billion in sales. Clarivate’s Drugs to Watch 2025 report includes treatments that were approved last year or expected to debut this year and ...